Cargando…

A Novel Once-Daily Fixed-Dose Combination of Memantine Extended Release and Donepezil for the Treatment of Moderate to Severe Alzheimer’s Disease: Two Phase I Studies in Healthy Volunteers

BACKGROUND: Combining two standard-of-care medications for Alzheimer’s disease (AD) into a single once-daily dosage unit may improve treatment adherence, facilitate drug administration, and reduce caregiver burden. A new fixed-dose combination (FDC) capsule containing 28 mg memantine extended releas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boinpally, Ramesh, Chen, Laishun, Zukin, Stephen R., McClure, Natalie, Hofbauer, Robert K., Periclou, Antonia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488451/ https://www.ncbi.nlm.nih.gov/pubmed/26016820 http://dx.doi.org/10.1007/s40261-015-0296-4

Ejemplares similares

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease
por: Deardorff, William James, et al.
Publicado: (2016)

Pharmacogenetics of Donepezil and Memantine in Healthy Subjects
por: Ovejero-Benito, María C., et al.
Publicado: (2022)

Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial)
por: Knapp, Martin, et al.
Publicado: (2016)

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
por: Jones, Rob, et al.
Publicado: (2009)

Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer's Disease: A Review of Clinical Trials
por: Molino, Ivana, et al.
Publicado: (2013)

Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis
por: Atri, Alireza, et al.
Publicado: (2015)

Single‐Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2018)

Effect of donepezil and memantine on improvement of cognitive function in patients with temporal lobe epilepsy
por: Oustad, Marjan, et al.
Publicado: (2020)

Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans
por: Chen, Laishun, et al.
Publicado: (2015)

Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer’s disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity
por: Koola, Maju Mathew, et al.
Publicado: (2018)

Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans
por: Jakate, Abhijeet, et al.
Publicado: (2020)

Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial
por: Jakate, Abhijeet, et al.
Publicado: (2019)

Donepezil plus memantine versus donepezil alone for treatment of concomitant Alzheimer’s disease and chronic obstructive pulmonary disease: a retrospective observational study
por: Cao, Yangyi, et al.
Publicado: (2020)

Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy
por: Atri, Alireza, et al.
Publicado: (2013)

A randomized, multicenter trial assessing the effects of rapastinel compared to ketamine, alprazolam, and placebo on simulated driving performance
por: Su, Shengfang, et al.
Publicado: (2021)

A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single‐Dose, Phase 1 Crossover Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis
por: Chen, Ruey, et al.
Publicado: (2017)

Memantine, Donepezil, or Combination Therapy—What is the best therapy for Alzheimer’s Disease? A Network Meta‐Analysis
por: Guo, Jiaxun, et al.
Publicado: (2020)

A prospective cohort conversion study of twice-daily to once-daily extended-release tacrolimus: role of ethnicity
por: Glick, Lauren, et al.
Publicado: (2014)

A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers
por: Zaltzman, Jeffrey S, et al.
Publicado: (2014)

Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil
por: Kano, Osamu, et al.
Publicado: (2013)

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
por: Li, Dan-Dan, et al.
Publicado: (2019)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
por: Buhl, Roland, et al.
Publicado: (2012)

Bioequivalence Study of Donepezil Hydrochloride Tablets in Healthy Male Volunteers
por: Rojanasthien, Noppamas, et al.
Publicado: (2012)

A Randomized Double-blind Study to Assess the Skin Irritation and Sensitization Potential of a Once-weekly Donepezil Transdermal Delivery System in Healthy Volunteers
por: Sabbagh, Marwan N., et al.
Publicado: (2023)

The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase Inhibitors
por: Grossberg, George T., et al.
Publicado: (2013)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis
por: Kedia, Prashant, et al.
Publicado: (2007)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
Publicado: (2014)

LB6. EDP-938, a Novel RSV N-Inhibitor, Administered Once or Twice Daily Was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study
por: Coakley, Eoin, et al.
Publicado: (2019)

Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
por: Woodcock, Ashley, et al.
Publicado: (2011)

Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers
por: Kim, Yo Han, et al.
Publicado: (2015)

Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS
por: Navarro, Jordi, et al.
Publicado: (2016)

Formulation and Evaluation of Once Daily Minocycline Hydrochloride Extended Release Matrix Tablets
por: Keny, R. V., et al.
Publicado: (2009)

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
por: Oliveira, Lilliana, et al.
Publicado: (2011)

Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets
por: deVries, Tina, et al.
Publicado: (2019)

The Effect of Once-Daily Gabapentin Extended Release Formulation in Patients With Postamputation Pain
por: Knezevic, Nebojsa Nick, et al.
Publicado: (2019)

Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies
por: deVries, Tina, et al.
Publicado: (2019)

Twice‐Daily Doravirine Overcomes the Interaction Effect from Once‐Weekly Rifapentine and Isoniazid in Healthy Volunteers
por: Lam, Edwin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uhkb0p6a87icp65k2vcnllhnld